This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Bristol-Myers (BMY) Reports Phase II Data on Psoriasis Drug
by Zacks Equity Research
Bristol-Myers Squibb (BMY) announces encouraging data from a phase II study on plaque psoriasis candidate.
Incyte, Foundation Medicine Partner for Companion Diagnostics
by Zacks Equity Research
Incyte (INCY) inks an agreement with Foundation Medicine for the development of companion diagnostics (CDx) for Incy's selective FGFR Inhibitor, pemigatinib.
Merck's Keytruda Combo Gets Nod for Lung Cancer in Europe
by Zacks Equity Research
Merck's (MRK) Keytruda receives approval for treating nonsquamous non-small cell lung cancer in combination with chemotherapies in first-line setting.
Glaxo's Nucala Suffers Regulatory Setback, Gets CRL for COPD
by Zacks Equity Research
FDA issues a complete response letter to Glaxo's (GSK) application for label expansion of its asthma drug, Nucala for COPD.
Lilly (LLY) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Lilly (LLY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
AstraZeneca's Asthma Drug Gets Breakthrough Therapy Status
by Zacks Equity Research
AstraZeneca (AZN) and partner Amgen's asthma candidate, tezepelumab gets Breakthrough Therapy designation from the FDA.
Lilly, Teva, Pfizer & Others Await FDA Decisions in September
by Kinjel Shah
FDA grants approval to 34 new treatments this year so far.
Large Cap Pharma Stocks Staging a Comeback in Second Half
by Indrajit Bandyopadhyay
Strong earnings, rising demand and successful clinical studies are paving the way for a rebound in the large-cap pharma industry in the second half.
J&J Submits NDA to the FDA for Depression Drug in Adults
by Zacks Equity Research
Johnson & Johnson (JNJ) submits NDA to the FDA for esketamine nasal spray seeking approval for treatment-resistant depression in adults in the United States.
Endo (ENDP) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Endo (ENDP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Novo Nordisk's Ozempic Lowers Risk of Cardiovascular Events (revised)
by Zacks Equity Research
Novo Nordisk (NVO) announces post hoc results from SUSTAIN 6 study demonstrating that Ozempic consistently reduces the risk of major cardiovascular (CV) events across type II diabetes population.
AstraZeneca Up This Year So Far on Favorable Pipeline Updates
by Zacks Equity Research
AstraZeneca's (AZN) stock is on an upward trajectory this year. Let us have a look at the reasons for the same.
Sanofi's Blood Disorder Drug Cablivi Gets Approval in Europe
by Zacks Equity Research
Sanofi's (SNY) Cablivi receives approval for the treatment of acquired thrombotic thrombocytopenic purpura, a rare blood clotting disorder.
Glaxo's Asthma Drug Gets EU Nod for Pediatric Population
by Zacks Equity Research
Glaxo (GSK) gains EU approval for asthma drug Nucala as an add-on treatment for severe refractory eosinophilic asthma in children.
AstraZeneca (AZN) Gets EU Nod for New Formulation of Bydureon
by Zacks Equity Research
AstraZeneca (AZN) gains EU approval for a new formulation of its diabetes medicine Bydureon ??? Bydureon BCise.
Novartis' Tafinlar/Mekinist Combo Gets EU Nod for 3rd Disease
by Zacks Equity Research
Novartis' (NVS) BRAF/MEK inhibitor combination, Tafinlar plus Mekinist, gets approval in the EU for adjuvant treatment of BRAF V600 mutation-positive melanoma.
Pfizer's Tafamidis Fails to Impress in Cardiomyopathy Study
by Zacks Equity Research
Pfizer's (PFE) tafamidis significantly reduces rate of mortality and cardiovascular-related hospitalization in patients with transthyretin amyloid cardiomyopathy. However, it fails to impress investors. Stock dips.
Novo Nordisk's Ozempic Lowers Risk of Cardiovascular Events
by Zacks Equity Research
Novo Nordisk (NVO) announces post hoc results from SUSTAIN 6 study demonstrating that Ozempic consistently reduces the risk of major cardiovascular (CV) events across type II diabetes population.
Is Eli Lilly (LLY) a High-Growth Dividend Stock?
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.
5 Reasons Why You Should Add Lilly Stock to Your Portfolio
by Zacks Equity Research
Here are five reasons which investors may consider while investing in Lilly's (LLY) stock.
Pharma Stock Roundup: FDA Blow for AGN, Label Expansion Nod for MRK, BMY Cancer Drugs
by Zacks Equity Research
Allergan (AGN) gets CRL for uterine fibroids candidate, Esmya. Merck (MRK) and Bristol-Myers' (BMY) PD-L1 inhibitors get FDA approval for expanded labels.
Pfizer Amends Xtandi Study Protocols to Speed Up Completion
by Zacks Equity Research
Pfizer (PFE) and Astellas Pharma announce amendment of protocols for two phase III studies evaluating Xtandi in hormone-sensitive prostate cancer, advancing anticipated completion date.
J&J to Appeal as Judge Confirms Jury Order in Talc Case
by Zacks Equity Research
Johnson & Johnson's (JNJ) suffers setback as Missouri judge confirms talc lawsuit jury verdict. The company intends to appeal against the decision.
Large-Cap Pharma Rebounds: 2 Stocks to Boost Your Portfolio
by Kinjel Shah
The large-cap pharma industry is on track to recovery. Here are two stocks from the space that investors may consider betting on.
Allergan Falls on FDA's Rejection of Uterine Fibroids Drug
by Zacks Equity Research
FDA rejects Allergan's (AGN) new drug application for Esmya for the treatment of abnormal uterine bleeding in women with uterine fibroids, citing safety issues.